Literature DB >> 16823914

Proteoliposome derived cochleate as novel adjuvant.

Gustavo Bracho1, Miriam Lastre, Judith del Campo, Caridad Zayas, Domingo González, Danay Gil, Reinaldo Acevedo, Carlos Taboada, Rosa L Solís, Oliver Pérez.   

Abstract

Cochleate structures (CS) consist in a highly stable lipid structures that have been reported to be a good antigen delivery system. The incorporation of pathogen associated molecular pattern (PAMP) from bacterial membranes into CS became in a promising approach to develop adjuvants, particularly mucosal adjuvants. Therefore, we prepare CS from proteoliposome (PL) obtained from Neisseria meningitidis B (PLCS) and evaluated it for its capability to stimulate the immune system as well as the adjuvant activity. The ability of PLCS to induce Thl polarization was also explored. The results and the easy capability for new antigen incorporation on CS support its use as adjuvant for immunization with a large variety of pathogen derived antigens and different routes of immunization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16823914     DOI: 10.1016/j.vaccine.2005.01.108

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Toxicological Assessment of the Cochleate Derived from Neisseria meningitidis Proteoliposome in Sprague Dawley Rats.

Authors:  Juan Francisco Infante-Bourzac; Sergio Sifontes-Rodríguez; Daniel Francisco Arencibia-Arrebola; Tamara Hernández-Salazar; Mildrey Fariñas-Medina; Oliver Pérez
Journal:  N Am J Med Sci       Date:  2012-03

2.  Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes.

Authors:  Nya L Fraleigh; Reynaldo Oliva; Jordan D Lewicky; Alexandrine L Martel; Reinaldo Acevedo; García-Rivera Dagmar; Hoang-Thanh Le
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

3.  Mucosal vaccine adjuvants update.

Authors:  Joon Haeng Rhee; Shee Eun Lee; Soo Young Kim
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31

4.  AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5.

Authors:  Gustavo Bracho; Caridad Zayas; Lina Wang; Ross Coppel; Oliver Pérez; Nikolai Petrovsky
Journal:  Malar J       Date:  2009-02-27       Impact factor: 2.979

5.  Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1).

Authors:  Nya L Fraleigh; Justin Boudreau; Nitin Bhardwaj; Nelson F Eng; Yanal Murad; Robert Lafrenie; Reinaldo Acevedo; Reynaldo Oliva; Francisco Diaz-Mitoma; Hoang-Thanh Le
Journal:  Heliyon       Date:  2016-08-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.